Detalles de la búsqueda
1.
Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study.
Respir Res
; 24(1): 229, 2023 Sep 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37749551
2.
Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study.
Respir Res
; 25(1): 152, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38561735
3.
Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Respir Res
; 19(1): 19, 2018 01 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-29370819
4.
Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective.
Cost Eff Resour Alloc
; 16: 17, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29773969
5.
The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada - the IMPACT trial.
Respir Med
; : 107694, 2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38844004
6.
Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany.
Int J Chron Obstruct Pulmon Dis
; 19: 945-956, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38646606
7.
Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study.
BMJ Open Respir Res
; 11(1)2024 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38772900
8.
Clinical, economic, and humanistic burden of asthma in Canada: a systematic review.
BMC Pulm Med
; 13: 70, 2013 Dec 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-24304726
9.
Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK.
Int J Chron Obstruct Pulmon Dis
; 18: 1815-1825, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37636901
10.
Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review.
Int J Chron Obstruct Pulmon Dis
; 18: 719-731, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37151760
11.
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
Int J Chron Obstruct Pulmon Dis
; 18: 407-418, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36998390
12.
Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting ß2-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England.
Int J Chron Obstruct Pulmon Dis
; 18: 231-245, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36908830
13.
Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK.
Int J Chron Obstruct Pulmon Dis
; 18: 2673-2685, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38022832
14.
DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach.
Adv Ther
; 40(10): 4282-4297, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37382864
15.
Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting ß2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England.
Int J Chron Obstruct Pulmon Dis
; 18: 643-659, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37155496
16.
Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study.
Int J Chron Obstruct Pulmon Dis
; 18: 2933-2953, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38089540
17.
Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England.
Int J Chron Obstruct Pulmon Dis
; 18: 2039-2054, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37731774
18.
Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England.
Int J Chron Obstruct Pulmon Dis
; 18: 1431-1444, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37465818
19.
The aging Canadian population and hospitalizations for acute myocardial infarction: projection to 2020.
BMC Cardiovasc Disord
; 12: 25, 2012 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-22471314
20.
Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England.
Int J Chron Obstruct Pulmon Dis
; 17: 1455-1466, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35769225